Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142440
Corporate User License Price USD 6000
Corporate User License Price INR 427320
Site License Price USD 4000
Site License Price INR 284880
Request a Quote

Report Title

Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017



Executive Summary

Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV spreads most commonly through bodily fluids. EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 7, 2, 1 and 2 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Epstein-Barr Virus (HHV-4) Infections-Overview

Epstein-Barr Virus (HHV-4) Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Epstein-Barr Virus (HHV-4) Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Epstein-Barr Virus (HHV-4) Infections-Companies Involved in Therapeutics Development

Advenchen Laboratories LLC

Arno Therapeutics Inc

bluebird bio Inc

Cell Medica Ltd

Epiphany Biosciences Inc

Genocea Biosciences Inc

Omeros Corp

TC BioPharm Ltd

Theravectys SA

Viracta Therapeutics Inc

Vironika LLC

ViroStatics srl

Epstein-Barr Virus (HHV-4) Infections-Drug Profiles

apatinib mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baltaleucel-T-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for EBV Associated Malignancies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for EBV Associated PTLD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Systemic Lupus Erythematosus, Epstein-Barr Viral Infections and Multiple Sclerosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Viral Infections Post-HSCT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Calcineurin A for EBV Associated Post Transplant Lymphoproliferative Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBViNT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr virus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEN-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MVA vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OmnImmune-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prelym-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate ZTA for Epstein-Barr Virus (HHV-4) Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EBNA1 for Epstein-Barr Virus Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viralym-M-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viroprev-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VRx-3996-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epstein-Barr Virus (HHV-4) Infections-Dormant Projects

Epstein-Barr Virus (HHV-4) Infections-Product Development Milestones

Featured News & Press Releases

Dec 01, 2016: ViraCyte Announces Oral Presentations on Viralym-M Clinical Trial Results at the 58th American Society of Hematology Annual Meeting

Aug 18, 2016: Vironika Secures Phase I SBIR Funding From NIH To Develop Inhibitors For EBV Lytic Reactivation

Jun 02, 2014: Vironika Receives Phase II SBIR Grant From NIH To Continue The Development Of EBV Latency Inhibitors

Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Advenchen Laboratories LLC, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Arno Therapeutics Inc, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by bluebird bio Inc, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Cell Medica Ltd, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Epiphany Biosciences Inc, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Genocea Biosciences Inc, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Omeros Corp, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by TC BioPharm Ltd, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Theravectys SA, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Viracta Therapeutics Inc, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by Vironika LLC, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Pipeline by ViroStatics srl, H2 2017

Epstein-Barr Virus (HHV-4) Infections-Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Advenchen Laboratories LLC

Arno Therapeutics Inc

bluebird bio Inc

Cell Medica Ltd

Epiphany Biosciences Inc

Genocea Biosciences Inc

Omeros Corp

TC BioPharm Ltd

Theravectys SA

Viracta Therapeutics Inc

Vironika LLC

ViroStatics srl

Epstein-Barr Virus (HHV-4) Infections Therapeutic Products under Development, Key Players in Epstein-Barr Virus (HHV-4) Infections Therapeutics, Epstein-Barr Virus (HHV-4) Infections Pipeline Overview, Epstein-Barr Virus (HHV-4) Infections Pipeline, Epstein-Barr Virus (HHV-4) Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person